China Regenerative Medicine International Limited (HKG:8158)
Hong Kong · Delayed Price · Currency is HKD 0.5200
-0.0300 (-5.45%)
Jul 25, 2025, 2:19 PM HKT
HKG:8158 Revenue
In the year 2024, China Regenerative Medicine International had annual revenue of 90.62M HKD with 30.41% growth. China Regenerative Medicine International had revenue of 15.42M in the quarter ending December 31, 2024, a decrease of -136.21%.
Revenue
90.62M
Revenue Growth
+30.41%
P/S Ratio
1.75
Revenue / Employee
2.59M
Employees
36
Market Cap
158.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 90.62M | 21.13M | 30.41% |
| Dec 31, 2023 | 69.49M | 27.95M | 67.29% |
| Dec 31, 2022 | 41.54M | -241.36M | -85.32% |
| Dec 31, 2021 | 282.90M | 100.76M | 55.32% |
| Dec 31, 2020 | 182.14M | 162.77M | 840.54% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Apr 30, 2017 | Pro | Pro | Pro |
| Apr 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |